Internal Medicine, Hematology & Oncology · Miami, FL
NPI
1750517959
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1475 NW 12th Ave # D8-4
Miami, FL, 33136
Phone (305) 243-8986
Groups this clinician bills Medicare through
Medicare paid, 2024
$19K
180 services
Medicare patients, 2024
44
Average age 75
Drug cost, 2024
$5.5M
611 prescriptions
Company payments, 2025
$5,867
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Justin M Watts was code 99233 (hospital e&m - subsequent), 103 times for 19 patients. In total Justin M Watts billed 180 services in 9 codes, and Medicare paid $19K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-02-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 103 | 19 | $99.55 | $10K |
| 99215 Office E&M - Established | Facility | 44 | 23 | $115.09 | $5,064 |
| 99223 Hospital E&M - Initial | Facility | 16 | 13 | $145.50 | $2,328 |
By year: 2022 $29K for 280 services; 2023 $25K for 228 services; 2024 $19K for 180 services.
Medicare prescription drug claims, 2024
In 2024, the drug Justin M Watts prescribed most often to Medicare patients was Venclexta (Venetoclax), with 103 prescriptions and refills. In total Justin M Watts wrote 611 Medicare prescriptions that cost $5.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Venclexta Venetoclax | 103 | 104 | 32 | $331K |
| Acyclovir Generic | 60 | 84 | 16 | $355 |
| Ojjaara Momelotinib Dihydrochloride | 44 | 44 | Under 11 | $1.2M |
| Levofloxacin Generic | 30 | 32 | Under 11 | $81.67 |
| Idhifa Enasidenib Mesylate | 30 | 30 | Under 11 | $1.1M |
| Hydroxyurea Generic | 27 | 73 | 13 | $666 |
| Imatinib Mesylate Generic | 26 | 26 | Under 11 | $30K |
| Jakafi Ruxolitinib Phosphate | 23 | 23 | Under 11 | $293K |
| Bosulif Bosutinib | 19 | 19 | Under 11 | $287K |
| Cresemba Isavuconazonium Sulfate | 16 | 16 | Under 11 | $97K |
| Prednisone Generic | 15 | 15 | Under 11 | $32.28 |
| Tibsovo Ivosidenib | 14 | 14 | Under 11 | $463K |
| Sprycel Dasatinib | 14 | 14 | Under 11 | $141K |
| Revlimid Lenalidomide | 13 | 13 | Under 11 | $203K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 13 | 13 | Under 11 | $16.14 |
Brand drugs: 345 claims; generic drugs: 266 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Justin M Watts $5,867 ($5,867 in general payments such as food, travel and fees) from 13 companies. The largest payer was Servier Pharmaceuticals LLC with $2,720.
| Company | Payments | Amount |
|---|---|---|
| Servier Pharmaceuticals LLC | 1 | $2,720 |
| Amgen Inc. AMGN | 2 | $2,191 |
| Rigel Pharmaceuticals, Inc. RIGL | 6 | $545 |
| Daiichi Sankyo Inc. 4568.T | 1 | $151 |
| GlaxoSmithKline, LLC. GSK | 4 | $103 |
| Geron Corporation GERN | 2 | $43.26 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $39.94 |
| Janssen Biotech, Inc. JNJ | 1 | $33.63 |
| Stemline Therapeutics Inc. | 1 | $20.95 |
| Incyte Corporation INCY | 1 | $20.03 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.